Skip to content

Trial Summary

 The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.


Z0011001 (ZN-c3-016)

ACTRN/NCT /ethics:


Scientific title:

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Sponsor / Cooperative group:

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Trial & Patient Characteristics

Cancer TypeMetastatic Colorectal Cancer
Trial TypeTreatment
PhasePhase I & Phase II
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-02-27
Anticipated End Date2026-09-25

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorTim Price
Recruitment StatusRecruiting